Parikh Asit

Director Asit Parikh bought 10,000 shares (10.0K shares) at blended avg $2.50 on PHAT; stock down 88.3% from 52-week high.

Asit Parikh, a Director at Phathom Pharmaceuticals, executed 2 purchases totaling 10,000 shares for $24,984.50 on May 6–7, 2025, at a blended average price of $2.50, increasing his holdings by 11.7% to 95,500 shares. The timing is noteworthy: the current stock price of $2.29 is 88.3% below the 52-week high of $19.50, and the stock has declined 46.1% in the prior 30 days and 59.9% in the prior 90 days. However, Parikh's prior trades at PHAT reveal a pattern of poor timing: across 5 measurable prior purchases at this ticker, none achieved positive 90-day returns, with outcomes ranging from +10.4% (30-day on a March 2025 buy) to -48.1% (90-day on a December 2024 buy). The company is unprofitable ($-94.3M net income in the latest fiscal year) despite strong revenue growth of +8001.5% year-over-year, though quarterly revenue stands at only $28.5M. This purchase occurs in a heavily distressed context with no clear evidence that prior buys at depressed valuations by this director have proven prescient.

Director Parikh Asit buys 10,000 shares of PHAT at $4.42; stock down 75.2% from $19.50 high, post-transaction holdings 85.5K shares.

Parikh Asit purchased 10,000 shares at $4.42 on 2025-03-13, increasing his holdings by 13.2% to 85.5K shares total. The timing arrives amid severe price deterioration: PHAT trades at $4.84, down 75.2% from its 52-week high of $19.50, and has declined 16.1% over the past 30 days and 42.2% over 90 days. His prior trades at PHAT show a poor timing pattern overall—only 1 of 5 prior buys achieved positive 90-day returns, with the most recent purchase (2024-12-13) returning -14.6% at 30 days and -48.1% at 90 days. Fundamentally, the company remains unprofitable with a net loss of $-85.6M against revenue of $16.4M, though annual revenue growth reached 8001.5%, suggesting a very early-stage or loss-making commercialization phase.

Director Parikh Asit bought 10,000 shares of PHAT at $8.12; stock -56.0% over 90 days, -58.3% from 52-week high.

Director Parikh Asit purchased 10,000 shares at $8.12 on 2024-12-13, increasing his holdings by 15.3% to 75,500 shares. The stock has declined sharply—down 56.0% over the past 90 days and 58.3% from its 52-week high of $19.50—creating unfavorable timing for the purchase. At this same ticker, Parikh's prior three buys from November 2023 each showed 90-day losses (-9.2%, -13.9%, -13.9%), and only 1 of his 4 prior PHAT buys was well-timed at the 90-day mark. The company remains unprofitable with negative net income of $-85.6M against quarterly revenue of $16.4M, limiting fundamental tailwinds for recovery.